首页 >>2015年12期
2005–2014年河南省15岁以上艾滋病患者抗病毒治疗后生存分析
作者:杨文杰 樊盼英 梁妍 聂玉刚 李宁 孙定勇 朱谦 王哲

摘要:

目的  了解河南省艾滋病患者抗病毒治疗后生存状况,并探讨生存时间的影响因素。方法  在"中国疾病预防控制系统-艾滋病综合防治信息系统"中下载河南省接受国家免费抗病毒治疗的≥15岁患者数据库,采用回顾性研究方法。纳入标准:2005年1月到2014年12月首次接受国家免费艾滋病抗病毒治疗,开始治疗时年龄为≥15岁,有完整的基线信息和随访信息。采用寿命表法计算患者生存率,采用Cox比例风险回归模型分析患者抗病毒治疗后生存时间的影响因素。结果  本研究共纳入30 376例研究对象,随访观察期内因艾滋病相关疾病死亡3 927例,病死率为3.2/100人年(3 927/122 350.6)。开始抗病毒治疗1、5、10年的累积生存率分别为93.7%、85.3%和78.4%。多因素分析显示,男性(HR=1.28,95%CI:1.20~ 1.37)、年龄越大(HR=1.20, 95%CI:1.16~ 1.24)、除结婚或同居外的其他婚姻状况(HR=1.20,95%CI:1.12~ 1.29)、基线时症状数越多(HR=1.11, 95%CI:1.07~ 1.14)、初始治疗方案为司坦夫定(D4T)或齐多夫定(AZT)+去羟肌苷(DDI)+奈韦拉平(NVP)或依非韦伦(EFV)(HR= 1.12, 95%CI:1.04~ 1.20)、最近1次随访显示近7 d漏服抗病毒药物(HR=18.36, 95%CI:17.08~ 19.74)的艾滋病患者抗病毒治疗后死亡风险大;同性性传播途径(HR=0.59, 95%CI:0.40~ 0.87)、基线CD4+T淋巴细胞计数水平越高[相对于0~ 200个/μl组,201~ 350个/μl组、351~ 500个/μl组和501~个/μl组,HR(95% CI)值分别为0.57(0.53~ 0.62)、0.43(0.37~ 0.49)、0.33(0.27~ 0.40)]、教育程度越高(HR= 0.89, 95% CI:0.83~ 0.95)的艾滋病患者抗病毒治疗后死亡风险小。结论  河南省艾滋病患者抗病毒治疗后生存率较高,开始治疗的年龄越大、男性、初始治疗方案为D4T或AZT+DDI+NVP或EFV、基线CD4+T淋巴细胞计数水平越低、最近1次随访显示近7 d漏服抗病毒药物的艾滋病患者抗病毒治疗后生存时间较短。

关键词:HIV;抗病毒药物;存活率;影响因素

Abstract:

Objective  To investigate the survival rate of AIDS patients after receiving antiretroviral therapy(ART) in Henan province and to determine factors associated with survival status.Methods  Database of AIDS patients receiving ART were downloaded from China Information System for Disease Preventioin and Control-AIDS, retrospective study method was conducted to analyze the information. Inclusion criteria: initially received national free ART during January, 2005 to December, 2014; aged 15 years or above; and with relatively complete baseline information and follow-up information. The accumulated survival rate of AIDS patients was calculated by life table method and the influencing factors were analyzed by Cox proportional hazard model.Results  Total 30 376 AIDS patients were enrolled in this study. During the follow-up period, a total of 3 927 cases died from HIV/AIDS related diseases. The mortality of all patients was 3.2/100 person year. After 1, 5, 10 years after the initiation of ART, the rates of accumulate survival rate were 93.7%, 85.3%, and 78.4%, respectively. Stepwise regression was used to conduct the time multiple factors analysis, the results showed that man (HR=1.28, 95%CI: 1.20-1.37), older age (HR=1.20, 95% CI: 1.16-1.24), others marital status except marrage or cohabitation (HR=1.20,95% CI: 1.12-1.29), more number of symptoms (HR=1.11, 95%CI: 1.07-1.14), initial treatment were main stavudine (D4T) or zidovudine (AZT)+ didanosine(DDI)+ nevirapine (NVP) or efevirenz (EFV) (HR=1.12, 95% CI: 1.04-1.20), missing drug in the past 7 days (HR=18.36,95%CI: 17.08-19.74) among AIDS patients had high mortality risk, homosexuality sexual transmission (HR=0.59, 95% CI: 0.40-0.87), higher baseline count of CD4+T lymphocyte(relative to 0-200 cells/μl group, HR(95%CI) were 0.57(0.53-0.62), 0.43(0.37-0.49), 0.33 (0.27-0.40) in 201-350 cells/μl group, 351-500 cells/μl group, and ≥501 cells/μl group, respectively), higher educations (HR=0.89, 95% CI: 0.83-0.95) had low mortality risk.Conclusion  Survival rate was higher after initial antiretroviral treatment among AIDS patients in Henan province. AIDS patient will have shorter survival time after antiviral treatment under one or more following conditions: higher age, male, initial treatment with D4T or AZT + DDI + NVP or EFV, lower baseline CD4 + T lymphocyte count, ever missed antiviral drugs in past 7 days of latest follow-up.

Key words: AIDS;Antiviral agents;Survival rate;Effect factor

发表日期:2015/12

引用本文:

图/表:

  • 10.3760/cma.j.issn.0253-9624.2015.12.009.T001:表1 河南省30 376例首次加入抗病毒治疗≥15岁艾滋病患者的基本情况

    10.3760/cma.j.issn.0253-9624.2015.12.009.T001:表1 河南省30 376例首次加入抗病毒治疗≥15岁艾滋病患者的基本情况

  • 10.3760/cma.j.issn.0253-9624.2015.12.009.T002:表2 河南省首次加入抗病毒治疗≥15岁艾滋病患者抗病毒治疗后生存状况

    10.3760/cma.j.issn.0253-9624.2015.12.009.T002:表2 河南省首次加入抗病毒治疗≥15岁艾滋病患者抗病毒治疗后生存状况

  • 10.3760/cma.j.issn.0253-9624.2015.12.009.T003:表3 河南省30 376例首次加入抗病毒治疗≥15岁艾滋病患者生存时间单因素Cox比例风险模型分析结果

    10.3760/cma.j.issn.0253-9624.2015.12.009.T003:表3 河南省30 376例首次加入抗病毒治疗≥15岁艾滋病患者生存时间单因素Cox比例风险模型分析结果

  • 10.3760/cma.j.issn.0253-9624.2015.12.009.T004:表4 河南省30 376例首次加入抗病毒治疗≥15岁艾滋病患者生存时间多因素Cox比例风险模型分析结果

    10.3760/cma.j.issn.0253-9624.2015.12.009.T004:表4 河南省30 376例首次加入抗病毒治疗≥15岁艾滋病患者生存时间多因素Cox比例风险模型分析结果

参考文献:

[1]StaszewskiS, Morales-RamirezJ, TashimaKT, et al.Efavirenz plus zidovudine and lamivudine,efavirenz plus indinavir,and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adult.Study 006 Team[J].N Engl J Med, 1999, 341(25):1865–1873.
[2]ZhangF, DouZ, YuL, et al.The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China[J].Clin Infect Dis,2008, 47(6): 825–833.
[3]DabisF, NewellML, HischelB.HIV drugs for treatment, and for prevention[J].Lancet,2010, 375(9731):2056–2057.
[4]ZhangF, DouZ, MaY, et al.Effect of earlier initiation of antiretroviral treatment And increased treatment coverage on HIV-related mortality in China:a national observational cohort study[J].Lancet Infect Dis,2011, 11(7):516–524.
[5]孙定勇,王奇,杨文杰,等.河南省2003–2009年艾滋病抗病毒治疗患者生存状况分析[J].中华流行病学杂志, 2012, 33(2):181–184.
[6]ZhangF, DouZ, MaY, et al.Five-year outcomes of the China National Free Antiretroviral Treatment Program[J].Ann Intern Med,2009, 151(4):241–251.
[7]原琛利,王芳,穆生财,等.山西省艾滋病抗病毒治疗后生存时间及影响因素分析[J].中华预防医学杂志,2014, 48(11): 1012–1015.
[8]郝连正,朱晓艳,王国永,等.艾滋病抗病毒治疗死亡患者的生存时间及相关因素分析[J].中华预防医学杂志,2014, 48(6):466–470.
[9]张广,龚煜汉,王启兴,等.四川省凉山州2004–2012年接受抗病毒治疗的艾滋病患者生存状况分析[J].中华流行病学杂志,2014, 35(12):1329–1332.
[10]邱涛,丁萍,刘晓燕,等.江苏省200例HIV感染者和艾滋病患者抗病毒治疗5年效果分析[J].中华预防医学杂志, 2014, 48(11):947–952.
[11]DouZ, XuJ, JiaoJH, et al.Gender difference in 2-year mortality and immunological response to ART in an HIV-infected Chinese population,2006-2008[J].PLos One, 2011, 6(8):e22707.
[12]MaY, ZhaoD, YuL, et al.Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in China[J].Clin Infect Dis,2010, 50(2): 264–271.
[13]NozakiI, DubeC, KakimotoK, et al.Social factors affecting ART adherence in rural settings in Zambia[J].AIDS Care, 2011, 23(7):831–838.
[14]周琳,吴琼海,沈伟伟,等.浙江省台州市接受抗病毒治疗的艾滋病患者生存分析[J].中华疾病控制杂志,2013, 17(12): 1049–1051.
[15]杨文杰,樊盼英,梁妍,等.2008-2013年河南省艾滋病患者抗病毒治疗对HIV的抑制效果及其影响因素分析[J].中华预防医学杂志,2015, 49(1):13–20.
[16]姚璇,詹发先,彭国平.湖北省艾滋病抗病毒治疗终止原因分析[J].中国艾滋病性病,2006, 12(6):495–497, 500.
[17]DavisDH, SmithR, BrownA, et al.Early diagnosis and treatment of HIV infection:magnitude of benefit on short-term mortality is greatest in older adults[J].Age Ageing,2013, 42(4):520–526.
[18]MetallidisS, TsachouridouO, SkouraL, et al. Older HIV-infected patients-an underestimated population in northern Greece:epidemiology,risk of disease progression and death[J].Int J Infect Dis,2013, 17(10):883–891.

用户评论 0条

用户名: 密码: 登陆 注册
 
  • 9
  • 3
  •  4 : 页次:0/0页 共0条记录 5条/每页
    关于我们 | 专家风采 | 会员注册 | 继续教育
    地 址:北京市西城区东河沿街69号正弘大厦511室 邮 编:100052
    电话:010-51322302
    版权所有 中华医学会及中华预防医学杂志编辑部
    京ICP备 07035254 号